Skip to main content

Table 1 Patients’ Characteristics of Primary and Validation Cohorts

From: 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

Characteristics Primary cohort (n = 71) Validation cohort (n = 36) P
Methylated (n = 39) Unmethylated (n = 32) P Methylated (n = 20) Unmethylated (n = 16) P
Age (mean ± SD, years) 50.72 ± 14.01 50.50 ± 14.82 0.95 46.70 ± 12.45 58.33 ± 11.95 0.08 0.65
Gender    0.97    0.45 0.84
 Male 23 19 10 10  
 Female 16 13 10 6  
Weight (mean ± SD, kg) 67.24 ± 12.36 64.20 ± 10.11 0.27 69.05 ± 14.74 66.28 ± 9.56 0.50 0.45
Metabolic Pattern    0.20    0.02 0.34
 Cystic 23 14   15 6   
 Solid 16 18   5 10   
WHO Grading    0.05    0.08 0.11
 Low Grade Glioma 13 2   11 2   
 High Grade Glioma 26 30   9 14   
SUVmax 9.18 ± 4.05 10.51 ± 4.45 0.20 9.89 ± 4.11 7.84 ± 3.28 0.11 0.33
SUVmean 4.00 ± 2.10 4.60 ± 1.86 0.22 4.31 ± 2.01 3.40 ± 1.59 0.14 0.36
  1. Abbreviations: SD Standard deviation, WHO World Health Organization, SUV Standard uptake value
  2. Note: Chi-Square or Fisher Exact tests, as appropriate, were used to compare the differences in categorical variables, while the independent sample t-test was used to compare the differences in age